Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Unlocking Health Canada's cache of trade secrets: mandatory disclosure of clinical trial results.

Literature DB >> 21876028

Unlocking Health Canada's cache of trade secrets: mandatory disclosure of clinical trial results.

Matthew Herder¹.

Abstract

Mesh：

Substances：
Prescription Drugs

Year: 2011 PMID： 21876028 PMCID： PMC3273507 DOI： 10.1503/cmaj.110721

Source DB: PubMed Journal: CMAJ ISSN： 0820-3946 Impact factor: 8.262

× No keyword cloud information.

12 in total

1. Clinical trial registration: a statement from the International Committee of Medical Journal Editors.

Authors: Catherine De Angelis; Jeffrey M Drazen; Frank A Frizelle; Charlotte Haug; John Hoey; Richard Horton; Sheldon Kotzin; Christine Laine; Ana Marusic; A John P M Overbeke; Torben V Schroeder; Harold C Sox; Martin B Van Der Weyden
Journal: Ann Intern Med Date: 2004-09-08 Impact factor: 25.391

2. Antidepressants and adverse effects in young patients: uncovering the evidence.

Authors: Andrew Herxheimer; Barbara Mintzes
Journal: CMAJ Date: 2004-02-17 Impact factor: 8.262

3. Failing the public health--rofecoxib, Merck, and the FDA.

Authors: Eric J Topol
Journal: N Engl J Med Date: 2004-10-06 Impact factor: 91.245

Review 4. Moving from opacity to transparency in pharmaceutical policy.

Authors: Irfan Dhalla; Andreas Laupacis
Journal: CMAJ Date: 2008-02-12 Impact factor: 8.262

5. Trial registration and results disclosure: impact of US legislation on sponsors, investigators, and medical journal editors.

Authors: Laurence Hirsch
Journal: Curr Med Res Opin Date: 2008-05-06 Impact factor: 2.580

6. Can Health Canada protect Canadians from unsafe drugs?

Authors: Paul C Hébert; Matthew B Stanbrook; Noni MacDonald; Ken Flegel; Jane Coutts; Stuart MacLeod
Journal: CMAJ Date: 2011-04-18 Impact factor: 8.262

Review 7. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data.

Authors: Craig J Whittington; Tim Kendall; Peter Fonagy; David Cottrell; Andrew Cotgrove; Ellen Boddington
Journal: Lancet Date: 2004-04-24 Impact factor: 79.321

8. The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada.

Authors: G Ross Baker; Peter G Norton; Virginia Flintoft; Régis Blais; Adalsteinn Brown; Jafna Cox; Ed Etchells; William A Ghali; Philip Hébert; Sumit R Majumdar; Maeve O'Beirne; Luz Palacios-Derflingher; Robert J Reid; Sam Sheps; Robyn Tamblyn
Journal: CMAJ Date: 2004-05-25 Impact factor: 8.262

7. Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study.

Authors: Joel Lexchin
Journal: BMJ Open Date: 2014-02-18 Impact factor: 2.692

7 in total

Unlocking Health Canada's cache of trade secrets: mandatory disclosure of clinical trial results.

1. Clinical trial registration: a statement from the International Committee of Medical Journal Editors.

2. Antidepressants and adverse effects in young patients: uncovering the evidence.

3. Failing the public health--rofecoxib, Merck, and the FDA.

Review 4. Moving from opacity to transparency in pharmaceutical policy.

5. Trial registration and results disclosure: impact of US legislation on sponsors, investigators, and medical journal editors.

6. Can Health Canada protect Canadians from unsafe drugs?

Review 7. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data.

8. The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada.

9. Selective publication of antidepressant trials and its influence on apparent efficacy.

10. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation.

1. North American regulatory agencies can and should make clinical trial data publicly available.

2. Health Canada and the pharmaceutical industry: a preliminary analysis of the historical relationship.

Review 3. Regulating prescription drugs for patient safety: does Bill C-17 go far enough?

4. Health Canada's use of its priority review process for new drugs: a cohort study.

5. Quality and quantity of information in summary basis of decision documents issued by health Canada.

6. On what basis did Health Canada approve OxyContin in 1996? A retrospective analysis of regulatory data.

7. Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study.